Carisma Therapeutics (NASDAQ:CARM) Stock Price Down 1.8%

Carisma Therapeutics, Inc. (NASDAQ:CARM) fell 1.8% on Thursday . The stock traded as low as $1.53 and last traded at $1.60. 163,645 shares changed hands during trading, an increase of 6% from the average session volume of 154,870 shares. The stock had previously closed at $1.63.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CARM. BTIG Research initiated coverage on Carisma Therapeutics in a research report on Thursday, April 11th. They set a “buy” rating and a $6.00 target price on the stock. HC Wainwright cut their price target on Carisma Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $8.80.

Carisma Therapeutics Stock Performance

The firm has a fifty day moving average of $2.15 and a 200-day moving average of $2.45. The stock has a market capitalization of $66.46 million, a price-to-earnings ratio of -0.46 and a beta of 1.00. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.01.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings data on Monday, April 1st. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $4.29 million for the quarter, compared to analyst estimates of $4.00 million. Carisma Therapeutics had a negative return on equity of 154.04% and a negative net margin of 582.34%. As a group, sell-side analysts anticipate that Carisma Therapeutics, Inc. will post -1.65 EPS for the current year.

Hedge Funds Weigh In On Carisma Therapeutics

A hedge fund recently bought a new stake in Carisma Therapeutics stock. SG Americas Securities LLC purchased a new position in Carisma Therapeutics, Inc. (NASDAQ:CARM) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 13,653 shares of the company’s stock, valued at approximately $58,000. 44.27% of the stock is currently owned by institutional investors and hedge funds.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.